Sudarshan Pharma Industries Ltd — Important, 18-05-2026: Company Update

Sudarshan Pharma's Board, at its meeting, approved issuing up to US$ 20 million in 8.00% Senior Unsecured Foreign Currency Convertible Bonds (FCCBs) due 2029. This strategic move, valued at approximately Rs. 191.86 Crore, aims to bolster the company's capital. Upon conversion, these FCCBs could lead to the issuance of around 6.35 crore new equity shares, based on a floor price of Rs. 30.19 per share. This fundraising initiative provides a clear path for the company to enhance its financial flexibility and support future growth, offering investors a convertible debt option.